American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: http://www.sciepub.com/journal/ajmcr Editor-in-chief: Samy, I. McFarlane
Open Access
Journal Browser
Go
American Journal of Medical Case Reports. 2020, 8(10), 361-362
DOI: 10.12691/ajmcr-8-10-10
Open AccessCase Report

Spontaneous Tumor Lysis Syndrome in Myeloproliferative Disorder: A Rarely Reported Clinical Entity

Sadaquat Liaqat1, Asghar Marwat1 and Munawwar Hussain1,

1Department of Internal Medicine, Conemaugh Health System, Johnstown PA 15905, USA

Pub. Date: July 03, 2020

Cite this paper:
Sadaquat Liaqat, Asghar Marwat and Munawwar Hussain. Spontaneous Tumor Lysis Syndrome in Myeloproliferative Disorder: A Rarely Reported Clinical Entity. American Journal of Medical Case Reports. 2020; 8(10):361-362. doi: 10.12691/ajmcr-8-10-10

Abstract

Tumor lysis syndrome (TLS) is an oncologic emergency resulting from a massive breakdown of tumor cells. It causes electrolyte imbalance and acute renal failure. It occurs after the initiation of chemotherapy. Spontaneous tumor lysis syndrome is seen in Burkitt's lymphoma, acute lymphoid leukemia, diffuse large B-cell lymphoma, and solid tumors like breast and prostate cancer. Spontaneous tumor lysis syndrome is exceedingly rare in patients with myeloproliferative disorders. We report a rare case of spontaneous tumor lysis in an 82-year-old female patient with a myeloproliferative disorder.

Keywords:
tumor lysis myeloproliferative spontaneous

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Al-Kali, A., Farooq, S., & Tfayli, A. (2009). Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia. Journal of Clinical Pharmacy and Therapeutics, 34(5), 607-610.
 
[2]  Belay, Y., Yirdaw, K., & Enawgaw, B. (2017). Tumor Lysis Syndrome in Patients with Hematological Malignancies. Journal of Oncology, 2017.
 
[3]  Cairo, M. S., & Bishop, M. (2004). Tumour lysis syndrome: New therapeutic strategies and classification. British Journal of Haematology, 127(1), 3-11.
 
[4]  Howard, S. C., Jones, D. P., & Pui, C. H. (2011). The tumor lysis syndrome. The New England journal of medicine, 364(19), 1844-1854.
 
[5]  Idrees, M., Fatima, S., & Bravin, E. (2019). Spontaneous Tumor Lysis Syndrome: A Rare Presentation in Breast Cancer. Journal of Medical Cases, 10(1), 24-26-26.
 
[6]  Eaddy, M., Seal, B., Tangirala, M., Davies, E. H., & O’Day, K. (2010). Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients. American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists, 67(24), 2110-2114.